期刊文献+

肺癌患者血清肿瘤标志物联合检测的临床意义 被引量:9

Clinical significance of combined detection serum tumor markers in patients with lung cancer
在线阅读 下载PDF
导出
摘要 目的探讨肿瘤标志物癌胚抗原(CEA)、糖类抗原153(CA153)、糖类抗原199(CA199)及铁蛋白(SF)单项及联合检测对肺癌诊断的价值。方法对70例肺癌患者、68例良性肺疾病患者及62例健康对照组进行CEA、CA153、CA199及SF的检测,并计算上述指标单项及联合检测在肺癌诊断中的敏感度和特异度。结果肺癌组CEA、CA153及CA199水平明显高于良性肺病组及健康对照组(P<0.05)。4项标记物在不同病理类型肺癌中CEA、CA153及CA199总体比较均有差异,其中肺腺癌CEA及CA153水平高于其他类型(P<0.05),小细胞肺癌CA199水平高于其他类型(P<0.05)。4项肿瘤标记物联合检测的敏感度(87.7%)明显高于单项敏感度(分别为62.3%、56.1%、57.3%和62.4%)。结论CEA、CA153、CA199及SF联合检测可明显提高肺癌的检出率,联合检测对于鉴别肺癌与肺部良性疾病、肺癌不同病理分型有一定的参考价值。 Objective To study the clinical significance of single or combination detection serum tumor markers CEA,CA153 ,CA199 and SF in patients with lung cancer. Methods The CEA,CA153 ,CA199 and SF were assayed in 70 patients with lung cancer,68 patients with benign lung disease and 62 cases of normal control. The sensitivities and specificities of different tumor markers and the combined for the diagnosis of lung cancer were evaluated and compared. Results The levels of serum CEA,CA153,CA199 and SF in lung cancer patients were significantly higher than that in benign lung disease patients and normal controls( P 〈 0.05). The lexel of CEA and CA153 in ad- enoearcinoma were significantly higher than that of other pathology types( P 〈 0.05 ) , and the level of CA 199 in small cell lung cancer was significantly higher than that of other pathology types( P 〈 0.05). The sensitivity of combination detection(87.7% )were significantly higher than that of single item(62.3% ,56.1% ,57.3% and 62.4% ,respectively). Conclusion The combined detection of CEA, CA153, CA199 and SF could increase the diagnostic sensitivity of lung cancer, it was proved to be as useful reference for differentiation of the lung cancer and benign lung diseases, even for different pathology types.
出处 《疑难病杂志》 CAS 2010年第1期22-24,共3页 Chinese Journal of Difficult and Complicated Cases
关键词 肺癌 肿瘤标志物 联合检测 Lung cancer Tumor markers Combined detection
  • 相关文献

参考文献10

  • 1Lutterbuese R, Raum T, Kischel R. et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competively inhibited by soluble CEA [ J ]. J Immunother, 2009,32 ( 4 ) : 341- 352.
  • 2Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumor and inflammatory markers in lung cancer [ J ]. Anticancer Res, 2007,27 ( 4A ) : 1911 - 1915.
  • 3Charalabopoulos K, Karakosta A, Bablekos G, et al. CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers [ J ]. Med Oncol, 2007,24(2) :219-225.
  • 4Molina R, Auge JM, Escudero JM. et al. Mucins CA125, CA199, CA153 and TAG-723 as tumor markers in patients with lung cancer: comparison with CYFRA211 ,CEA,SCC and NSE [ J]. Tumor Biol,2008,29 (6) : 371-380.
  • 5LI CS, Cheng BC, Ge W. et al. Clinical value of CYFRA21-1, NSE, CA153, CA199 and CA125 assay in the elderly patients with pleural effusions[ J ]. Int J Clin Pract ,2007,61 (3) :444-448.
  • 6叶江枫,解立新,陈勇,杜永红.血清肿瘤标志物与肺癌的关系[J].临床肺科杂志,2008,13(7):832-834. 被引量:18
  • 7陈锋,李为民,王冬梅,高蜀生,包勇,陈文彬,刘丹.联合检测血清肿瘤标志物在肺癌诊断中的价值[J].四川大学学报(医学版),2008,39(5):832-835. 被引量:36
  • 8赵翔,路平.肿瘤标记物联合检测在肺癌诊断中的价值[J].中国医药,2009,4(1):1-2. 被引量:11
  • 9陈连周,李纬明,李运泉,王东,李雯,汪谦.血清五种主要肿瘤标志物联合检测在肺癌诊断中的临床价值[J].中国医药,2008,3(10):617-618. 被引量:8
  • 10Kukulj S,Jaganjae M, Boranic M,et al. Altered iron metabolism,inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer[J ]. Med Oncol,2009,24. [ Epub ahead of print].

二级参考文献26

  • 1罗素霞,陈小兵,肖毅军,王瑞林.肺癌相关血清学肿瘤标志物研究进展[J].癌症进展,2005,3(3):252-256. 被引量:24
  • 2马少锋,陈江谊.恶性肿瘤相关物质(TSGF)在诊断小儿恶性肿瘤中的应用[J].中华小儿外科杂志,2004,25(5):408-410. 被引量:5
  • 3李蓉,李睿.肺癌肿瘤标记物研究进展[J].国外医学(肿瘤学分册),1996,23(2):98-103. 被引量:29
  • 4陈贡斌.健择联合卡铂治疗老年中晚期非小细胞肺癌的临床研究[J].中国医药,2006,1(11):663-665. 被引量:2
  • 5Salgia R, Harpole D, Hemdon JE, et al. Role of serum tumor markers CA125 and CEA in non-small cell lung cancer. Anticancer RES,2001, 21 (2B) :1241 - 1246.
  • 6Sawabata N, Ohta M, Takeda S, et al. Serum carcinoembryonic anti- gen level in surgically resected clinical stage Ⅰ patients with non-small cell lung cancer. Ann Thorac Surg. 2002 ;74( 1 ) :174 -179.
  • 7D'Cunha J, Corfits AL, Herndon JE 2nd, et al. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage Ⅰ non - small cell lung cancer-preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg. 2002 ; 123 ( 3 ) :484 - 491.
  • 8Alatas F, Alatas Q, Metintas M, et al. Diagnostic value of CEA.CA15- 3 ,CA19-9,CYFRA21-1 ,NSE and TSA assay in pleural effusions. Lung Cancer. 2001,31 ( 1 ) :9 - 16.
  • 9Gu CD, Osaki T, Oyama T,et al. Detection of micrometastatic tumor ceils in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann Surg. 2002; 235(1) :133 -9.
  • 10Schneider J, Velcovsky HG, Morr H, et al. Comparison of the tumor markers tumor M2-PK,CEA,CYFRA21-1 ,NSE and SCC in the diagnosis of lung cancer. AntiCancer Res,2000, 20(6D) :5053 -5058.

共引文献67

同被引文献104

引证文献9

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部